Innovation


Innovation Publication

Research during Coronavirus for services, durables and technology

Innovating in Challenging Times – Issue 2
Food & Beverage Publication

2019 China Food and Beverage Packaging Trend Observation

From “Visibility” to “Interaction”. Packaging design is one of the most important parts of establishing the product image and generating the marketing strategy.

Regional Roles for Ipsos India Senior Honchos

Vidya Sen picks up APAC role for Ipsos Innovation; Arun Agarwala takes up additional charge of APEC markets of
Philippines, Indonesia & Vietnam as IT Head

Curation Publication

Human Curation in an AI world

Human curation is more important than ever in an age of ‘Infobesity’ as it offers qualities that are not replicable by AI. We show how a fusion of AI synthesis and strategic human curation can help to drive business impact.
Social Media Survey

Ipsos reinforces its Social Media Intelligence capabilities with the acquisition of Synthesio

Ipsos is pleased to announce the acquisition of Synthesio for an amount of over USD50 million in cash.
Innovation Publication

Four Ways Agile Research Will Evolve to Drive Innovation

In today’s fast-moving, shape-shifting world, it seems virtually every business, every marketer, and every researcher wants to be agile. But, what exactly does agility mean?
Innovation Publication

Smartificial Intelligence

Artificial Intelligence is often mooted as the ‘future’ for our industry. Many lead us to believe that we are headed for an AI utopia; that ‘optimised’ ad experiences fuelled by big data insights gleaned solely by machines, tailored to individuals, and served to them programatically with impeccable timing in the right time and right context, is almost within reach. However, when we take a step back to consider this, how close are we really; and is it even what we want at all?
Innovation Publication

Conquering Complexity: The Coming Revolution in Oncology Biomarker Testing

Despite the advent of targeted therapies and the associated rise in the use of companion and complementary diagnostics, we are only just emerging from the initial exploratory stages of oncology biomarker testing. As will be argued in this paper, we are on the cusp of a much more radical revolution, and the molecular diagnostics landscape is set to change dramatically in the coming decades. It is crucial that any company entering this space prepare for this imminent upheaval and plan their launch strategy accordingly.